Brief: Wuxi Biologics Adds 69 Projects In Jan-April, Maintains Expected Revenue Growth
31/05/2026 11:37
BRIEF-Wuxi Biologics Adds 69 Projects In Jan-April, Maintains Expected Revenue Growth May 31 (Reuters) - WuXi Biologics (Cayman) Inc 2269.HK:
SAYS ADDED 69 NEW PROJECTS IN JAN-APRIL, MAINTAINS EXPECTED REVENUE GROWTH OF 13-17% Y/Y
Further company coverage: 2269.HK
(Reporting by Beijing Newsroom)
((Ethan.Wang@thomsonreuters.com;))
Recent news on WuXi Biologics (Cayman)
See all newsWuXi Biologics hits 6-week high on confidence in delivering FY26 guidance
Brief: Wuxi Biologics Adds 69 Projects In Jan-April, Maintains Expected Revenue Growth
Viridian Therapeutics signs manufacturing deal with WuXi Biologics for thyroid eye disease drug
WuXi Biologics climbs most in six weeks on share repurchase plan
Brief: Wuxi Biologics To Repurchase Shares Up To Us$400 Million In Open Market